Ferric carboxymaltose vs Ferric derisomaltose
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Iron repletion · full Heart Failure pipeline
Ferric carboxymaltose · Injectafer / Ferinject
Marketed by Daiichi Sankyo and partners
NCT03037931 · Phase 3 · completed
This double-blind, randomized, placebo-controlled trial (HEART-FID) assigned 3,065 ambulatory patients with heart failure, an ejection fraction of 40% or less and iron deficiency to ferric carboxymaltose or placebo. The primary outcome was one hierarchical composite of death, heart failure hospitalization and 6-minute walk distance, tested at a significance level of 0.01. The win ratio was 1.10 (99% CI 0.99 to 1.23, P=0.02), which did not reach that level, and the authors report no apparent difference between the groups, so the primary endpoint was missed. The figures come from the peer-reviewed primary report (Mentz et al., N Engl J Med 2023).
Next expected readout: December 2026 · NCT05793996 (registry estimate)
Reported efficacy
Number of Deaths (1 year); Number of Hospitalizations for Heart Failure (1 year); Change in 6MWT (Six Minute Walk Test) Distance (6 months): Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. (missed)
Result source: NCT03037931
Ferric derisomaltose · Monoferric / Monofer
Marketed by Pharmacosmos and partners
NCT00537186 · Phase 3 · completed
This was a small, open-label, single-arm study of intravenous iron isomaltoside in patients with chronic heart failure and iron deficiency anaemia who needed parenteral iron. It had no comparison group, and all of its primary outcomes were safety measures, so there is no primary comparison that can be met or missed. A published pilot study with the same sponsor, design and size (20 patients) reported no treatment-related adverse reactions over 8 weeks. Results were not posted on ClinicalTrials.gov.
Next expected readout: August 2027 · NCT06427343 (registry estimate)
Reported efficacy
Adverse events (AE) (Number and type of AE) (Eight weeks after enrollment); Serious adverse events (SAEs) (Eight weeks after enrollment); Physical examination (At screening visit and at end of study); Vital signs (At every visit); Clinical laboratory tests (biochemistry, haematology) (At every visit): Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks. (not_applicable)
Result source: NCT00537186
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ferric carboxymaltose | Ferric derisomaltose |
|---|---|---|
| CV death or HF hospitalisation | —Not posted · NCT03833336 | —Not posted · NCT04945707 |
| HF hospitalisation | 25.4% vs 32.4%−7 vs placeboNCT02937454 | —Not posted · NCT04945707 |
| CV death | —Not posted · NCT03833336 | —Not posted · NCT04945707 |
| KCCQ clinical summary, change | —Not posted · NCT03833336 | —Not posted · NCT04945707 |
CV death or HF hospitalisation
- Ferric carboxymaltose
- —Not posted · NCT03833336
- Ferric derisomaltose
- —Not posted · NCT04945707
HF hospitalisation
- Ferric carboxymaltose
- 25.4% vs 32.4%−7 vs placeboNCT02937454
- Ferric derisomaltose
- —Not posted · NCT04945707
CV death
- Ferric carboxymaltose
- —Not posted · NCT03833336
- Ferric derisomaltose
- —Not posted · NCT04945707
KCCQ clinical summary, change
- Ferric carboxymaltose
- —Not posted · NCT03833336
- Ferric derisomaltose
- —Not posted · NCT04945707
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ferric carboxymaltose: 4 of 4 rows · Ferric derisomaltose: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ferric carboxymaltose |
|---|---|
| Dropout rate | 26.7%a NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3 show 2 more results24.7%FCM (Ferric Carboxymaltose) NCT02937454 · Phase 4 · registry result, not featured evidence —Group 1 - FCM (Ferric Carboxymalto NCT02937454 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3 show 2 more results0%FCM (Ferric Carboxymaltose) NCT02937454 · Phase 4 · registry result, not featured evidence —Group 1 - FCM (Ferric Carboxymalto NCT02937454 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 27%a NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3 show 2 more results—FCM (Ferric Carboxymaltose) NCT02937454 · Phase 4 · registry result, not featured evidence 44.7%Group 1 - FCM (Ferric Carboxymalto NCT02937454 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a pneumonia 3.7% (placebo 2.3%) cardiac disorders 3.3% (placebo 3.4%) acute kidney injury 3% (placebo 2.6%) NCT03037931 · Phase 3 · pooled · Heart Failure · phase 3 show 1 more resultcardiac failure 9.1% (placebo 8.2%) NCT02937454 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ferric carboxymaltose
show 2 more results
show 6 more results
Chronic Kidney Disease
Shared mechanism: Iron repletion · full Chronic Kidney Disease pipeline
Ferric carboxymaltose · Injectafer / Ferinject
Marketed by Daiichi Sankyo and partners
NCT00317239 · Phase 3 · completed
The study randomized 255 participants to ferric carboxymaltose or active oral iron treatment, but it was open-label rather than blinded. Its primary endpoint was a surrogate hemoglobin response measure, and although the reported counts favored ferric carboxymaltose, statistical significance is not reported, so the result cannot be considered definitively met.
Reported efficacy
Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101 (unclear)
Result source: NCT00317239
Ferric derisomaltose · Monoferric / Monofer
Marketed by Pharmacosmos and partners
NCT02940860 · Phase 3 · completed
This was a large (n=1538), randomized, open-label, active-controlled Phase 3 trial of ferric derisomaltose versus iron sucrose in non-dialysis-dependent chronic kidney disease with iron deficiency anemia. The primary efficacy endpoint — change in hemoglobin from baseline to week 8 — met its prespecified non-inferiority margin (difference 0.08 g/dL; 95% CI -0.06 to 0.23, lower bound above -0.5 g/dL), and the co-primary safety endpoint of serious or severe hypersensitivity reactions was low in the ferric derisomaltose arm (3/1019, 95% CI upper bound 0.86%, below the 3% threshold). Although the trial was adequately powered with a hard clinical endpoint, it was open-label rather than double-blind, which is a meaningful design limitation.
Reported efficacy
Change in Hemoglobin (Hb) From Baseline to Week 8; Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions (Baseline to week 8): Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26) (met)
Result source: NCT02940860
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ferric carboxymaltose | Ferric derisomaltose |
|---|---|---|
| Kidney composite outcome | —Not reported | —Not posted · NCT00536666 |
| UACR, % change | —Not reported | —Not posted · NCT00536666 |
| eGFR slope | —Not reported | —Not posted · NCT00536666 |
| Haemoglobin, change | —Not reported | 1.2 vs 1.1vs Iron SucroseNCT029408606 other results
|
Kidney composite outcome
- Ferric carboxymaltose
- —Not reported
- Ferric derisomaltose
- —Not posted · NCT00536666
UACR, % change
- Ferric carboxymaltose
- —Not reported
- Ferric derisomaltose
- —Not posted · NCT00536666
eGFR slope
- Ferric carboxymaltose
- —Not reported
- Ferric derisomaltose
- —Not posted · NCT00536666
Haemoglobin, change
- Ferric carboxymaltose
- —Not reported
- Ferric derisomaltose
- 1.2 vs 1.1vs Iron SucroseNCT02940860
6 other results
- 0.6 vs 0.3 NCT01102413
- 1.1 vs 0.9 NCT02940860
- 0.8 vs 0.5 NCT02940860
- 0.4 vs 0.2 NCT02940860
- 0.9 vs 0.5 NCT01102413
- -0.1 vs -0.1 NCT01222884
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Ferric carboxymaltose: 4 of 5 rows · Ferric derisomaltose: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ferric carboxymaltose | Ferric derisomaltose |
|---|---|---|
| Hemoglobin Increase 1g/dL event count · % of participants | 60.4% (n=144) vs 34.7% (n=101) Ferrous Sulfate Tablets*a,b,c NCT00317239 · Phase 3 · monotherapy · converted to % from 87 participants as posted | 46.2% (n=1027) vs 44.2% (n=511) Iron Sucrose @ 8wk*a,b,c NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 · converted to % from 474 Participants as posted |
| Dropout rate | 8.8%d NCT00317239 · Phase 3 · monotherapy show 4 more results14.2%FCM (High Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence 11.7%FCM (Low Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence 2.7% NCT00548691 · Phase 3 · registry result, not featured evidence 18.1% NCT00317226 · Phase 3 · registry result, not featured evidence | 5.5%e NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 2 more results10.7% NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 10.3% NCT01222884 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —d NCT00317239 · Phase 3 · monotherapy show 4 more results—FCM (High Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence —FCM (Low Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence — NCT00548691 · Phase 3 · registry result, not featured evidence — NCT00317226 · Phase 3 · registry result, not featured evidence | —e NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 2 more results— NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 — NCT01222884 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 8.8%d NCT00317239 · Phase 3 · monotherapy show 4 more results25.3%FCM (High Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence 24%FCM (Low Ferritin Target) NCT00994318 · Phase 3 · registry result, not featured evidence 4.3% NCT00548691 · Phase 3 · registry result, not featured evidence 18.1% NCT00317226 · Phase 3 · registry result, not featured evidence | 8.1%e NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 2 more results5.3% NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 9.6% NCT01222884 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 3 more resultshypertension 13.6% oedema peripheral 13.6% urinary tract infection 11.7% NCT00994318 · Phase 3 · registry result, not featured evidence oedema peripheral 14% hypertension 9.3% back pain 8% NCT00994318 · Phase 3 · registry result, not featured evidence odema peripheral 7.1% hypertension 5.5% urinary tract infection 5.5% NCT00317226 · Phase 3 · registry result, not featured evidence | e hyperkalaemia 2.2% urinary tract infection 2.2% hypertension 1.4% NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 2 more resultsnasopharyngitis 3.1% pyrexia 3.1% diarrhoea 2.6% NCT01102413 · Phase 3 · monotherapy · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 fall 3% headache 3% c-reactive protein increased 2.6% NCT01222884 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation context differs: registered conditions differ.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
- ePopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ferric carboxymaltose
show 1 more result
Ferric derisomaltose
show 6 more results
Iron Deficiency Anemia
Shared mechanism: Iron repletion · full Iron Deficiency Anemia pipeline
Ferric carboxymaltose · Injectafer / Ferinject
Marketed by Daiichi Sankyo and partners
NCT00982007 · Phase 3 · completed
This open-label randomized trial enrolled 997 people with iron deficiency anemia in two cohorts: those who did not respond to oral iron were compared with oral ferrous sulfate, and others with intravenous standard-of-care iron. The primary endpoint was the rise to the highest hemoglobin by day 35. Ferric carboxymaltose raised hemoglobin more than the comparator in both cohorts (1.57 vs 0.80 g/dL and 2.90 vs 2.16 g/dL, p=0.001), so the primary endpoint was met. The figures come from the registry results and the sponsor's approval release.
Next expected readout: September 2027 · NCT06061393 (registry estimate)
Reported efficacy
Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. (Day 56); Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population. (Day 120): Primary efficacy endpoint, mean change to highest hemoglobin from baseline to day 56: ferric carboxymaltose 1.13 g/dL (n=1,249) vs iron sucrose 0.92 g/dL (n=1,244); treatment difference 0.21 g/dL (95% CI 0.13 to 0.28), statistically significant. Primary composite cardiovascular safety endpoint: 13.71% vs 12.14% (difference 1.57%, 95% CI -1.10% to 4.25%), no significant difference. (met)
Result source: NCT00981045
Ferric derisomaltose · Monoferric / Monofer
Marketed by Pharmacosmos and partners
NCT02940860 · Phase 3 · completed
This was a large (n=1538), randomized, open-label, active-controlled Phase 3 trial of ferric derisomaltose versus iron sucrose in non-dialysis-dependent chronic kidney disease with iron deficiency anemia. The primary efficacy endpoint — change in hemoglobin from baseline to week 8 — met its prespecified non-inferiority margin (difference 0.08 g/dL; 95% CI -0.06 to 0.23, lower bound above -0.5 g/dL), and the co-primary safety endpoint of serious or severe hypersensitivity reactions was low in the ferric derisomaltose arm (3/1019, 95% CI upper bound 0.86%, below the 3% threshold). Although the trial was adequately powered with a hard clinical endpoint, it was open-label rather than double-blind, which is a meaningful design limitation.
Next expected readout: November 2026 · NCT04913649 (registry estimate)
Reported efficacy
Change in Hemoglobin (Hb) From Baseline to Week 8; Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions (Baseline to week 8): Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26) (met)
Result source: NCT02940860
Results for Iron Deficiency Anemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Ferric carboxymaltose: 2 of 4 rows · Ferric derisomaltose: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ferric carboxymaltose | Ferric derisomaltose |
|---|---|---|
| Dropout rate | 2.7%a NCT00548691 · Phase 3 · registry result, not featured evidence | 5.5%b NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 1 more result8.7% NCT02962648 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00548691 · Phase 3 · registry result, not featured evidence | —b NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 1 more result— NCT02962648 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 4.3%a NCT00548691 · Phase 3 · registry result, not featured evidence | 8.1%b NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 1 more result12.7% NCT02962648 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — | b hyperkalaemia 2.2% urinary tract infection 2.2% hypertension 1.4% NCT02940860 · Phase 3 · Chronic Kidney Disease, Iron Deficiency Anemia · phase 3 show 1 more resultabdominal pain 2.9% anaemia 2.9% dizziness 2.9% NCT02962648 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ferric derisomaltose
show 3 more results
show 3 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ferric carboxymaltose's landscape · Ferric derisomaltose's landscape